Dynavax Technolo Stock Price, News & Analysis

Dynavax Technologies Corporation has partnered with Times Pharmacy and Hep Free Hawaii to provide HEPLISAV-B, the only FDA-approved two-dose hepatitis B vaccine, to at-risk populations in Hawaii, particularly people with diabetes. The vaccine is essential as individuals with diabetes are at higher risk for hepatitis B and related liver cancer. Vaccination aims to combat the high liver cancer rates in Hawaii, where it's the second highest in the U.S. HEPLISAV-B requires only two doses within a month, offering greater efficacy than previous vaccines.

Dynavax Technologies Corporation (Nasdaq: DVAX) announced that CEO Ryan Spencer will participate in a virtual fireside chat at the H.C. Wainwright Virtual Fireside Chat Series on June 25, 2020, at 10:50 a.m. E.T. Interested parties can access the presentation through the 'Events & Presentations' section on Dynavax's investor website. Dynavax is focused on developing and commercializing novel vaccines, including HEPLISAV-B®, a Hepatitis B vaccine. The company is also advancing its CpG 1018 adjuvant for COVID-19 and pertussis vaccines. For more details, visit www.dynavax.com.

Dynavax Technologies Corporation (Nasdaq: DVAX) has announced the completion of enrollment for a clinical trial evaluating HEPLISAV-B® in adults with end-stage renal disease (ESRD) undergoing hemodialysis, enrolling 119 patients. The company anticipates final immunogenicity data in Q4 2020. The study aims to assess a new 4-dose regimen of HEPLISAV-B, which could offer an important vaccination alternative in this high-risk population. However, safety and effectiveness of the vaccine have not yet been established in these patients.

Dynavax Technologies Corporation (Nasdaq: DVAX) announced that CEO Ryan Spencer will participate in a virtual fireside chat at the William Blair 40th Annual Growth Stock Conference on June 9 at 12:00 p.m. C.T. The presentation will be accessible via the Company’s website under the 'Events & Presentations' section. Dynavax is known for developing novel vaccines, including HEPLISAV-B, approved in 2018 for hepatitis B prevention in adults. The company is also advancing CpG 1018 as a vaccine adjuvant through partnerships.

Dynavax Technologies Corporation (Nasdaq: DVAX) has successfully closed its underwritten public offering of 16,100,000 shares at $5.00 per share, generating approximately $80.5 million in gross proceeds. The offering included the underwriters' option to purchase an additional 2,100,000 shares. Proceeds will be utilized to support the commercialization of HEPLISAV-B®, advance its CpG 1018 vaccine platform, and enhance general corporate purposes. The offering was managed by Cowen, Evercore ISI, and William Blair, with a shelf registration statement filed with the SEC.

Dynavax Technologies Corporation (Nasdaq: DVAX) has announced a public offering of 14,000,000 shares at $5.00 each, aiming to raise approximately $70 million. This offering, set to close around May 27, 2020, includes a 30-day option for underwriters to purchase an additional 2,100,000 shares. The funds will support the commercialization of HEPLISAV-B® and advancements in the CpG 1018 vaccine platform, potentially for COVID-19. The offering is conducted under a previously effective shelf registration statement filed with the SEC.

Dynavax Technologies Corporation (Nasdaq: DVAX) announced plans for an underwritten public offering to sell shares of its common stock, with a potential 15% over-allotment option for underwriters. Proceeds are intended to support the commercialization of HEPLISAV-B®, advance the CpG 1018 vaccine platform, and cover general corporate expenses. The offering follows a shelf registration statement effective since April 30, 2020. The company emphasizes that the timing and size of the offering depend on market conditions.

Dynavax Technologies Corporation (DVAX) reported Q1 2020 net product revenue of $10.5 million, up from $5.6 million in Q1 2019, driven by increased sales of HEPLISAV-B, despite COVID-19 challenges. The company achieved a seroprotection rate of 86.4% in preliminary results from a clinical trial for dialysis patients. While total R&D expenses decreased, SG&A expenses rose to $20.9 million. A net loss of $12.6 million was reported, an improvement from $39.7 million in the previous year. Dynavax maintains a strong cash position with $129.5 million as of March 31, 2020.